| TNF inhibitors (n=14) | Anakinra ( n=7) or Tocilizumab (n=3) | |
|---|---|---|
| Current age (years) | 37±13 | 35±10 |
| Age at diagnosis (years) | 26 (20–59) | 26 (5–46) |
| Follow up (months) | 72 (18–252) | 54 (26–288) |
| Gender (% males) | 31 | 46 |
| Sore throat (%) | 54 | 73 |
| Skin involvement (%) | 54 | 46 |
| Joint involvement (%) | 85 | 55 |
| Hepatotoxicity (%) | 31 | 46 |
| CRP (mg/L) | 115±88 | 131±78 |
| ESR (mm/h) | 101±30 | 102±32 |
| Ferritin (ng/ml) | 1000 (281–29979) | 1280 (424–5181) |